1. Home
  2. MRBK vs SGMO Comparison

MRBK vs SGMO Comparison

Compare MRBK & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meridian Corporation

MRBK

Meridian Corporation

HOLD

Current Price

$17.24

Market Cap

162.3M

Sector

Finance

ML Signal

HOLD

Logo Sangamo Therapeutics Inc.

SGMO

Sangamo Therapeutics Inc.

HOLD

Current Price

$0.45

Market Cap

155.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRBK
SGMO
Founded
2004
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
155.1M
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
MRBK
SGMO
Price
$17.24
$0.45
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$18.00
$4.71
AVG Volume (30 Days)
80.2K
9.2M
Earning Date
01-23-2026
11-06-2025
Dividend Yield
2.90%
N/A
EPS Growth
75.95
N/A
EPS
1.77
N/A
Revenue
$109,758,000.00
$32,875,000.00
Revenue This Year
$26.84
$1.37
Revenue Next Year
$8.90
N/A
P/E Ratio
$9.75
N/A
Revenue Growth
18.84
N/A
52 Week Low
$11.16
$0.38
52 Week High
$17.43
$2.84

Technical Indicators

Market Signals
Indicator
MRBK
SGMO
Relative Strength Index (RSI) 77.07 43.51
Support Level $16.25 $0.49
Resistance Level $16.59 $0.51
Average True Range (ATR) 0.33 0.04
MACD 0.13 0.01
Stochastic Oscillator 91.70 31.04

Price Performance

Historical Comparison
MRBK
SGMO

About MRBK Meridian Corporation

Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Share on Social Networks: